| Schedule of revenues disaggregated by category |
Revenues disaggregated by category were as follows (in thousands):
|
|
|
|
|
|
|
|
|
Three Months Ended March 31, |
|
|
2024 |
|
2023 |
Product sales: |
|
|
|
|
|
|
Gross product sales |
|
$ |
38,426 |
|
$ |
33,198 |
Discounts and allowances |
|
|
(12,423) |
|
|
(9,453) |
Total product sales, net |
|
|
26,003 |
|
|
23,745 |
Revenues from collaborations: |
|
|
|
|
|
|
Delivery of drug supplies, royalty and others |
|
|
3,531 |
|
|
2,325 |
Total revenues from collaborations |
|
|
3,531 |
|
|
2,325 |
Total revenues |
|
$ |
29,534 |
|
$ |
26,070 |
|
| Schedule of product revenue allowance and reserve categories |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Chargebacks, |
|
Government |
|
|
|
|
|
|
Discounts and |
|
and Other |
|
|
|
|
|
|
Fees |
|
Rebates |
|
Returns |
|
Total |
Balance as of January 1, 2024 |
|
$ |
8,236 |
|
$ |
3,517 |
|
$ |
3,931 |
|
$ |
15,684 |
Provision related to current period sales |
|
|
9,763 |
|
|
2,280 |
|
|
224 |
|
|
12,267 |
Credit or payments made during the period |
|
|
(10,255) |
|
|
(1,609) |
|
|
(42) |
|
|
(11,906) |
Balance as of March 31, 2024 |
|
$ |
7,744 |
|
$ |
4,188 |
|
$ |
4,113 |
|
$ |
16,045 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Chargebacks, |
|
Government |
|
|
|
|
|
|
|
|
Discounts and |
|
and Other |
|
|
|
|
|
|
|
|
Fees |
|
Rebates |
|
Returns |
|
Total |
Balance as of January 1, 2023 |
|
$ |
6,213 |
|
$ |
2,636 |
|
$ |
3,296 |
|
$ |
12,145 |
Provision related to current period sales |
|
|
7,231 |
|
|
1,795 |
|
|
197 |
|
|
9,223 |
Credit or payments made during the period |
|
|
(5,777) |
|
|
(1,422) |
|
|
(81) |
|
|
(7,280) |
Balance as of March 31, 2023 |
|
$ |
7,667 |
|
$ |
3,009 |
|
$ |
3,412 |
|
$ |
14,088 |
|